News
Maternal mental health start-up bags US$10.9m in series A funding
Seven Starling aims to help women navigate critical periods in their lives with evidence-based mental health support
The US start-up Seven Starling has secured US$10.9m in series A funding to address unmet needs in women’s mental health.
More than 90 per cent of women do not seek help for perinatal mood and anxiety disorders due to high barriers including a shortage of therapists, limited in-network coverage and mental health stigma.
These conditions affect one in five women during the motherhood journey, yet only 20 per cent are screened for mental health issues, and 75 per cent of those who need treatment do not receive it.
Seven Starling aims to address these challenges by making its services accessible through its in-network coverage, integrated group therapy model, and partnerships with referring providers to make the process of getting started easier for patients.
The investment round, led by RH Capital, is hoped to expand access to essential mental health services for women going through critical periods, such as infertility, miscarriage and loss, pregnancy, postpartum and motherhood.
“We are thrilled to have successfully raised this round of funding, which will allow us to expand our reach and help more women who need support during critical life transitions,” said Tina Beilinson Keshani, co-founder and CEO of Seven Starling.
“This investment is a testament to the demand for a dedicated women’s mental health solution and our commitment to providing accessible, high-quality care. With the new funding, we will continue to successfully reduce the stigma around women’s mental health and ensure that every woman has access to the care she needs, when she needs it.”
The capital raised from this round, Keshani said, would be used to “fuel” national expansion, partnering with Medicaid plans, and developing innovative technology to further integrate with healthcare partners.
Alice Zheng, principal at RH Capital, said: “We are proud to partner with Seven Starling in this new chapter to expand access to maternal mental healthcare, an area of significant need.
“We are excited by the comprehensive and scalable offerings, including group therapy to expand access. As a recent mum of two myself, I have been shocked by the lack of perinatal mental health support available relative to need and am thankful to see Seven Starling filling that gap.”
Mar Hershenson, founder of Pear VC, added: “Seven Starling is addressing a huge problem not just around motherhood but the entire female lifespace from adolescence to menopause.
“Women are nearly twice as likely as men to be diagnosed with depression or an anxiety disorder in their lifetime, but lack a tailored solution designed to meet their unique needs. Pear has partnered with Seven Starling since day one and we are excited to double down on them.”
Kelly Ernst, March of Dimes SVP, chief impact officer, said mental health conditions, such as depression and anxiety, are among the most common complications for women during pregnancy and the postpartum period.
“However, many do not receive treatment they desperately need, which can lead to long lasting clinical, social, and economic consequences,” she explained.
“When these conditions are effectively treated and managed, everyone benefits. We’re proud to be investors in Seven Starling and look forward to seeing how their innovative and comprehensive approach improves the mental healthcare needs of women across the country.”
To receive the Femtech World newsletter, sign up here.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Fertility4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







1 Comment